Short answer
Krystal Biotech, Inc. (KRYS) filed its Q3 2026 10-Q quarterly report on Nov 2, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $127M (up 30.2% year over year) with net income of $63M.
Q3 2026 key financials · XBRL
- Revenue
- $127M
- +30.2% YoY · +6.8% QoQ
- Net income
- $63M
- −20.5% YoY · +15.2% QoQ
- Operating margin
- 55.9%
- EPS (diluted)
- $2.04
- −23.3% YoY · +14.0% QoQ
Source: XBRL data from the Krystal Biotech, Inc. (KRYS) Q3 2026 10-Q on SEC EDGAR. USD.
Krystal Biotech, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 product revenue $127.3M, up $29.5M from $97.8M, driven by Europe and Japan launches
- Gross margin 94%; operating income $71.1M vs $41.4M, net income $63.1M vs $79.4M
- VYJUVEK strongest product line, $127.3M quarterly revenue; no comparable segment breakdown disclosed
- Cash, cash equivalents and short-term investments $911.9M; operating cash flow $246.4M year-to-date
- $400M share repurchase authorized; France pricing negotiations extend until at least 2027, EMERALD-1 enrollment slower than anticipated
Risk Factors
- New risk: $400 million stock repurchase program authorized in October 2026
- Most material update: repurchases may reduce cash available for clinical programs and VYJUVEK commercialization
- Regulatory risk: repurchases may incur a 1% U.S. federal excise tax
- Market risk: suspended or discontinued repurchases could adversely affect stock price
- Financial risk: program could diminish cash reserves without enhancing long-term stockholder value
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Krystal Biotech, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.